AngloGold Ashanti (AU) rose roughly 45% over the last 30 days, from about $74.88 to above $108 per share, driven by surging gold prices and a strong second-quarter earnings report. The company reported sharply higher profitability in Q2 2026, including EBITDA up 46% to $2 billion and a $2 billion share repurchase program, reinforcing investor confidence.
Investors are asking whether Cardiol Therapeutics (CRDL) can climb to the $5 level, a round psychological milestone and the low end of Wall Street's published price-target range. With shares recently trading near $1.90, reaching $5 would require roughly a 160% advance from current levels.
The $5 price target is not arbitrary — it matches the current street-high bull case, with H.C. Wainwright maintaining a $5 objective and BTIG carrying a $6 target. Reaching $5 from roughly $2.20 would require a gain of well over 100%, far above the consensus analyst price target of about $3.10.
MRK surged +13.04% to $152.80 on Wednesday, with gains beginning in premarket and accelerating during the regular session. The catalyst: Merck and Moderna announced positive Phase 3 INTerpath-001 results, the first late-stage win for an mRNA cancer vaccine.
The central question is whether SoFi Technologies (SOFI) can climb back to the $30 level, roughly 65% above its recent trading range near $18. The strongest bullish factors are a national bank charter, accelerating member and product growth, and a rapidly expanding fee-based revenue mix.
FEIM fell -8.65% to about $68.67 from a prior close of $75.17, declining during regular market hours on Wednesday. The drop followed Q4 fiscal 2026 results reported after the close on Aug. 18, with revenue of $15.4M missing the $18.6M consensus estimate.
EMAT fell -8.97% to $2.84 during the regular session, giving back most of the prior day's +11.83% rebound. The decline reflects profit-taking and fading "buy-the-dip" momentum after a sharp technical bounce off 52-week lows.
CENX fell -8.37% to $41.84 during regular trading hours, extending a pullback from its prior-session close of $45.66. The slide reflects profit-taking after a sharp rally, with traders locking in gains amid a broad unwind of the stock's hot momentum.
VICR fell -12.26% during regular trading, sliding to roughly $212.69 from a prior close of $242.41. The drop came despite strong Q2 results (EPS $1.04 vs. $0.65 estimate; revenue +49.3% YoY), signaling a "sell the news" profit-taking move.
BLZE fell -13.23% to about $16.66, down from a $19.20 prior-session close, during regular trading after gapping down at the open. The decline extended an after-hours slide triggered by the company's announcement of a $150 million convertible senior notes offering due 2031, plus a $22.5 million over-allotment option.
LZB is down -17.98%, falling from a prior close of $40.83 to about $33.49, with the decline beginning in after-hours trading Tuesday and gapping down at Wednesday's open. The drop was driven by a fiscal Q1 earnings miss: adjusted EPS of $0.43 versus a $0.49 consensus, and revenue of $475.7 million (down -3.4% YoY) versus roughly $501 million expected.
MSTR jumped roughly +13.4% intraday to about $104.91, up from Tuesday's $92.52 close, during regular market hours. Primary catalyst: Q2 13F filings showed 12 of the top 15 institutional holders added to MSTR positions, a net increase of roughly $1.2 billion in institutional ownership.
EL is up +17.68% to $99.17, versus the prior session close of $84.27, with gains beginning in premarket trading and extending into the regular session. The move was driven by fiscal Q4 results that beat estimates: adjusted EPS of $0.39 topped the $0.32 consensus, and revenue of $3.63B exceeded the $3.55B forecast.
MRNA is up roughly +103% to about $127.89 versus Tuesday's $62.96 close, with the surge beginning in premarket trading. The catalyst: Moderna and Merck announced their Phase 3 INTerpath-001 trial met its primary goal, with the personalized mRNA cancer vaccine intismeran plus Keytruda significantly improving recurrence-free survival in high-risk melanoma.
AEHR fell -7.08% intraday to roughly $114.53, extending the prior session's -15.4% slide. The drop occurred during regular trading hours amid a broad AI/semiconductor sell-off.
NBIS is down -9.36% during regular market hours, last near $225.17 versus a prior close of $248.43. Primary catalyst: a pre-market announcement of a proposed $4.5 billion convertible senior notes offering ($2.75B due 2030, $1.75B due 2034), plus exchange agreements tied to existing 2029/2031 notes.
BTBT is trading down roughly -14.48% intraday to about $1.24 from its $1.45 prior close, with the decline occurring during regular market hours. The sell-off extends post-earnings weakness: Q2 results on Aug. 13 showed a -$0.31 per-share loss, badly missing the -$0.05 consensus, and Northland Securities subsequently cut its Q3 estimates.
WYFI dropped -25.01% to $20.30 from the prior session's $27.07 close, extending a roughly -22% pre-market slump into regular trading. The slide followed pricing of an upsized $270 million convertible senior notes offering (raised from $250 million), carrying a 5% coupon due 2032.
MRNA is surging +85.17% in the session, climbing from a $62.96 prior close to roughly $116.58. The move ignited in premarket trading and extended into regular hours on positive clinical news.
The stock price target in focus is $150 , roughly 29% above Newmont's recent level near $116 and above its 52-week high of $134.88. The strongest bullish factors are record gold prices near $4,900 per ounce, a new $6 billion share buyback, and a refreshed leadership agenda.